(Press-News.org) Article Summary
Certain immune cells help breast cancer resist hormone therapy.
Sylvester researchers studied how blocking those cells with a new drug combo may help.
The approach could lead to better treatment options for tough-to-treat hormone therapy resistant breast cancer cases.
MIAMI, FLORIDA (EMBARGOED UNTIL NOV 5, 2025, AT 2:00 P.M. ET) – In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.
The findings were validated not only in preclinical studies but also in patient-derived explants, and are published in the Nov. 5, 2025, issue of Science Translational Medicine.
Endocrine therapy has long been a cornerstone for treating estrogen receptor-positive (ER+) breast cancer, but a significant number of patients eventually develop resistance to drugs like tamoxifen and fulvestrant, leading to poorer outcomes and limited treatment options.
The new research sheds light on why this resistance occurs—and how it might be overcome by targeting the cellular “bodyguards” in breast cancer cells.
To better understand the resistance mechanism, the research team focused on the tumor microenvironment and created two ER+ endocrine therapy resistant preclinical tumor models.
The tumor micoenvironment can be thought of as the “neighborhood” surrounding a tumor, filled with various cells that can either help or hinder cancer growth. Within this environment, tumor-associated macrophages (TAMs)—a type of immune cell—play a pivotal role, and the researchers found that a specific subtype of TAMs, marked by proteins called CD163 and PD-L1, are more abundant in patients whose tumors resist tamoxifen therapy. PD-L1 is a protein that helps cancer cells hide from the immune system. Drugs that block PD-L1, known as immune checkpoint inhibitors, have already revolutionized treatment for some cancers.
“These macrophages act like bodyguards for the cancer cells, helping them survive treatment,” said Rumela Chakrabarti, Ph.D., the study’s senior author and co-director of Sylvester’s Surgical Breast Cancer Research Group. “By understanding how they are brought to the tumor microenvironment and how they work, we can start to think about new ways to disrupt their support system.”
The research team discovered that these PD-L1+ TAMs are recruited to the tumor by a signaling molecule called DLL1, produced by the cancer cells themselves. DLL1 acts like a beacon, drawing in macrophages through a pathway dependent on CCR3/CCL7. Once in the tumor, these macrophages help maintain cancer stem cells—cells that can regenerate the tumor and are notoriously hard to kill with standard therapies. These immune suppressive macrophages also lead to exhaustion of the CD8-T cells, which kill the tumor cells.
In both preclinical studies and patient-derived tumor samples, higher levels of DLL1 and PD-L1+ TAMs were strongly linked to resistance against tamoxifen and fulvestrant, another common endocrine therapy. Notably, patients with a higher number of these cells in their tumors had worse survival rates.
To address this challenge, the team conducted preclinical studies to test a new combination therapy. By using antibodies that block DLL1 and PD-L1, alongside low-dose tamoxifen, they were able to shrink tumors, reduce the number of cancer stem cells, and reprogram the immune environment to be less supportive of cancer growth.
“This triple therapy approach could be a game-changer for patients whose cancers no longer respond to standard hormone treatments,” said Chakrabarti, who is also an Associate Professor of surgery at the Miller School. “It’s about hitting the cancer from multiple angles at once.”
The researchers acknowledge that more work is needed before this approach can be translated into patient care by extended in vivo modeling and pilot clinical trials. “Our models are robust, but human tumors are even more complex,” Dr. Chakrabarti noted. “We’re optimistic, but careful.”
Understanding the interplay between cancer cells and their microenvironment is crucial for developing next-generation therapies. This research highlights the importance of looking beyond the tumor itself and considering the “ecosystem” that supports it. It’s a reminder that cancer is not just a disease of rogue cells, but of complex cellular communities, said Chakrabarti.
“Every breakthrough brings us closer to a future where breast cancer is not just treatable, but truly manageable for every patient,” she said. “We’re committed to making that future a reality in the coming years.”
about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Authors: A complete list of authors is available in the paper.
Article Title: DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer
DOI: 10.1126/scitranslmed.adr6207
Funding and Disclosures: Available in the paper.
# # #
END
A collaborative research team has discovered that the Southern Ocean releases substantially more carbon dioxide (CO2) during the dark austral winter than previously thought. Their new study reveals that this winter outgassing has been underestimated by up to 40%.
The team comprises researchers from the Second Institute of Oceanography, Ministry of Natural Resources (SIO-MNR), and the Nanjing Institute of Geography and Limnology (NIGLAS) of the Chinese Academy of Sciences. Their findings were published in Science Advances on ...
In the summer of 2020, an international team led by a University of Arizona archaeologist reported the discovery of the largest monumental construction known today in the Maya area in the state of Tabasco, near Mexico's southeastern border.
The monument, found at a site called Aguada Fénix, measures nearly a mile long and a quarter-mile wide, ranges from 30 to 50 feet high and dates to 1,000 B.C.
In the five years since that discovery, the team, led by Regents Professor of anthropology Takeshi Inomata and Fred A. Reicker Distinguished Professor of anthropology Daniela Triadan, has pieced together evidence about Aguada ...
CAMBRIDGE, MA -- A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.
In the new study, a team of MIT biological engineers was able to identify a handful of immunogenic peptides, out of more than 4,000 bacterial proteins, that appear to stimulate a strong response from a type of T cells responsible for orchestrating immune cells’ response to infection.
There is currently only ...
HOUSTON – (Nov. 5, 2025) – Rice University applied physicist Junichiro Kono has been awarded the American Physical Society’s 2026 Frank Isakson Prize for Optical Effects in Solids.
The biennial prize recognizes outstanding optical research that leads to breakthroughs in the condensed matter sciences. Kono is being honored “for pioneering contributions to optical physics, light-condensed matter interactions and photonic applications of nanosystems, including artificial quantum structures and carbon-based nanomaterials.”
Kono’s ...
LA JOLLA, CA—During the first weeks of pregnancy, the developing placenta in a mother’s womb undergoes a dramatic change. Individual cells merge, forming a continuous barrier that will spend the next nine months ferrying oxygen and nutrients to the growing fetus while keeping the mother's immune system at bay. When this structure fails to form properly, pregnancies are at higher risk of complications, including preeclampsia and restricted fetal growth.
Now, scientists at Scripps Research have identified a key player in the placenta’s transformation—a molecule called galectin-3 that binds to sugar molecules on specific ...
Geneva, 5 November 2025 – The International Telecommunication Union (ITU) will join the global community at COP30 in Belém, Brazil, to advance the Green Digital Action initiative – a platform driving collective progress toward a sustainable digital future.
The ITU delegation, led by Deputy Secretary-General Tomas Lamanauskas, will work with governments, private-sector leaders, and civil society to leverage digital transformation as a catalyst for climate solutions and work toward a sustainable digital sector.
Why digital technologies at COP30 matter
As global demand for technology ...
Words matter — but your hands might matter more, according to a new UBC study which found that purposeful hand gestures can make speakers appear more competent and persuasive.
The Sauder School of Business research, analyzed 2,184 TED Talks using AI and automated video analysis. Researchers isolated more than 200,000 hand gestures into 10-second clips and compared them against audience engagement metrics, such as ‘likes’ on social media while controlling for factors like gender, occupation, language, ...
The Mount Sinai Health System today announced that it will implement Microsoft Dragon Copilot, a new AI clinical assistant designed to streamline clinical documentation, surface critical information, and automate administrative tasks across care settings. The rollout marks a major milestone in Mount Sinai’s ongoing digital transformation and its commitment to using responsible artificial intelligence to support clinicians and deliver better outcomes for patients.
Built on a modern, secure, and scalable architecture purpose-built for healthcare, Dragon Copilot integrates advanced natural language, ambient listening, and generative AI capabilities to help clinicians ...
Researchers at Karolinska Institutet and Yale University have created a multidimensional, molecular map of how the mouse brain develops after birth and how it reacts to inflammation. The study, which is published in Nature, shows that some of the molecular programmes that govern brain development can be reactivated in the brain during inflammation.
Brain development is a complex process involving, for example, the precise diversification and distribution of cells into distinct areas. The researchers behind the present study ...
Key points:
Metastatic melanoma cells that have spread to lymph nodes survive by relying on a protein called ferroptosis suppressor protein 1 (FSP1)—a finding that points to FSP1 inhibitors as a potentially effective treatment for cancer progression.
The study illuminates how metastasizing cancer cells can adapt to survive in lymph nodes, suggesting that treatments can be tailored to exploit cancer’s unique weaknesses according to where it is located in the body.
The study also highlights new ways to understand cancerous cell death using in vivo models of cancer metastasis.
Boston, ...
